Immuneering Corporation (IMRX) Discusses Expanded Atebimetinib Development: Pancreatic and Anaplastic Thyroid Cancer Trials - Slideshow

🇺🇸 Seeking Alpha (US) —
Immuneering Corporation (IMRX) Discusses Expanded Atebimetinib Development: Pancreatic and Anaplastic Thyroid Cancer Trials - Slideshow

AI Summary

Immuneering is expanding clinical development of atebimetinib to include trials for pancreatic and anaplastic thyroid cancers. The article highlights the expanded program, but provides no trial results in the supplied description.

Markets Health Immuneering atebimetinib pancreatic cancer anaplastic thyroid cancer clinical trials

Read original source →